诺华公司拟于2009年秋季在美国市场推出Extavia。患者除了可通过处方获得Extavia外，诺华公司还将为患者提供支持服务，其中包括开通护理咨询热线，一对一药物注射培训，以及医保报销指导服务。此外，生产厂家将提供自动注射器，以便于患者自行注射Extavia。

据诺华公司召开的新闻发布会宣称，研究表明，β-1b重组干扰素治疗可使MS的年复发率降低34% (P =0.0001)，服用Extavia的患者中未出现复发的人数几乎为安慰剂对照组的2倍(31% 对 16%, P =0.007)。另外，β-1b重组干扰素可延缓病程的进展。在研究中，在经历过单次神经系统疾病发作且病程≥ 24h的患者中有近75%在2年之后未进展至有临床表现的MS。

Legal Classification:

Rx

Adults:

≥18 years: initially 0.0625mg SC every other day; increase by 25% every 2 weeks to target dose of 0.25mg SC every other day.

Children:

<18 years: not recommended.

Precaution(s):

Depression. Suicidal ideation. Monitor CBC, differential, platelets, chemistries, liver function (at 1, 3, and 6 months then periodically). Thyroid disorders. Elderly. Pregnancy (Cat. C; may be abortifacient). Nursing mothers: not recommended.

Adverse Reaction(s):

Lymphopenia, neutropenia, leukoprnia, lymphadenopathy, headache, insomnia, incoordination, hypertension, dyspnea, abdominal pain, increased liver enzymes, rash, skin disorder, hypertonia, myalgia, urinary urgency, metrorrhagia, impotence, asthenia, flu-like symptoms, pain, peripheral edema, chest pain, malaise, injection site reactions/necrosis (suspend therapy if multiple lesions occur); anaphylaxis.

How Supplied:

Single-use vials—15 (w. prefilled diluent syringe, supplies)

Last Updated:

10/29/2009